A look at CheckMate-214 in 1L metastatic RCC

A look at the interim results from the BMS CheckMate-214 trial in renal cell carcinoma

August 16, 2017

PROSPECTing for nuggets with PROSTVAC in CRPC

A post mortem analysis of the Bavarian Nordic PROSTVAC cancer vaccine trial failure in CRPC

September 15, 2017

Can this novel combination overcome resistance to checkpoint blockade?

An early look at a new IO combination that may help overcome resistance to checkpoint therapy

September 14, 2017

ESMO17 Day 4 Highlights and Lowlights

A look at the last day of ESMO17 with key data on cancer vaccines, checkpoint and targeted therapies to explore

September 12, 2017

ESMO Day 3 Highlights and Lowlights

A roundup of the key trials and targets presented on Sunday at #ESMO17

September 10, 2017

ESMO17 Day 1 Highlights and Lowlights

A look at mostly lung cancer highlights from the first 2 days at #ESMO17

September 9, 2017

The changing face of ovarian cancer

Rucaparib likely joins the early maintenance PARP club in ovarian cancer with their ARIEL3 data at #ESMO17

September 7, 2017

ESMO Preview 5 – intriguing small biotech immunotherapies

A look at some of the small biotechs and what they're developing on IO front that looks intriguing at #ESMO17

September 6, 2017

ESMO Preview 4 – Rock around the clock

8 key ImmunoOnc studies being presented at #ESMO17 this month

September 4, 2017

ESMO17 Preview 3 – A look at HCC and Blueprint’s BLU-554

A look at the changing HCC market and how pipeline agents may (or may not) impact the landscape...

August 24, 2017

ESMO17 Preview 2 – The 5 on Targeted Therapy

An eclectic selection of important abstracts involving targeted therapies to watch out for at #ESMO17

August 17, 2017

ESMO17 Preview 1 – The IO 5

Top 5 IO oral abstracts to watch out for in Madrid

August 15, 2017